Connect your AI

MoonLake Immunotherapeutics MLTX Thereafter

Other financials

Income statement

Operating income-$70.0M-47.5%

Net income-$69.7M-74.5%

EPS (diluted)-$0.98-55.6%

Balance sheet

Cash & equivalents$298.5M+9.9%

Total debt$100.8M+33.3%

Total equity$254.0M-37.7%

Total assets$400.4M-21.7%

Cash flow

Operating cash flow-$66.3M-73.8%

CapEx--100%

Free cash flow-$66.3M-73.6%

Valuation

Market cap$1.49B-45.9%

Enterprise value$1.29B-50.0%

Returns & leverage

Return on equity-77.7%-221pp

Debt / equity0.4×+0.2×

Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept mnlk:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's thereafter.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is MoonLake Immunotherapeutics's thereafter?: MoonLake Immunotherapeutics (MLTX) reported thereafter of $0 in Q1 2026.